Please login to the form below
melanoma
This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
cancer indications as well as uptake in other indications such as adjuvant melanoma, bladder cancer and MSI-H cancers.
Latest news
-
Sanofi pays $160m upfront to acquire Tidal Therapeutics
with Merck &Co’s Keytruda (pembrolizumab) in patients with high-risk melanoma and other cancer types. ... BioNTech also has a number of mRNA-based candidates in development for the treatment of a number of cancer types, including advanced melanoma,
-
Keytruda growth helps Merck to offset COVID-19 impact in Q3
other areas including adjuvant melanoma and bladder cancer.
-
Seres’ microbiome-based therapy hits the mark in phase 3
This includes research into Seres’ phase 1b candidate SER-401, which is being investigated for its ability to improve the clinical outcomes of metastatic melanoma patients treated with currently-available immunotherapies.
-
Roche’s Tecentriq combo scores FDA approval for melanoma
Tecentriq, plus MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelboraf (vemurafenib), has been backed for the treatment of BRAF V600 mutation-positive advanced melanoma patients. ... The FDA approval of this Tecentriq combination represents an
-
Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC
In addition to lung cancer, Merck’s drug is approved for a host of other cancer types, including in China for advanced melanoma.
Sanofi pays $160m upfront to acquire Tidal Therapeutics
Keytruda growth helps Merck to offset COVID-19 impact in Q3
Seres’ microbiome-based therapy hits the mark in phase 3
Roche’s Tecentriq combo scores FDA approval for melanoma
Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC
More from news
Approximately 82 fully matching, plus 293 partially matching documents found.
Latest Intelligence
-
Surviving cancer: a new era for patients
In European patients, the average five-year relative survival rate was 83% for melanoma, 83% for prostate cancer, 82% for breast cancer and 57% for colon cancer.
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
targets of small cell lung cancer and melanoma in adults, while its licensing became embroiled in a royalties dispute.
-
Immuno-oncology in 2019: the rapid evolution continues
BMS led the charge when Opdivo became the first in its class to gain approval (in metastatic melanoma in December 2014 in Japan), but Merck &Co’s Keytruda has emerged as
-
Is China ready for a pharmaceutical gold rush?
China’s millions of tobacco smokers make for a large market, which may be why BMS filed for approval in lung cancer treatment, rather than melanoma, the leading indication in other
-
Combined immunotherapies – potential and pitfalls
The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.
Surviving cancer: a new era for patients
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Immuno-oncology in 2019: the rapid evolution continues
Combined immunotherapies – potential and pitfalls
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations, Keytruda has become a blockbuster immunotherapy as well as introducing a new standard-of-care for
-
Industry appointments
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
-
Packer Forbes appoints Jade McCudden
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
-
Array appoints Victor Sandor chief medical officer
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
-
Bruno Strigini leaves Merck & Co for Novartis
Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Industry appointments
Packer Forbes appoints Jade McCudden
Bruno Strigini leaves Merck & Co for Novartis
More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
You only have to think back to the first immunotherapy data in metastatic melanoma or for PARP inhibitors in ovarian cancer to know how compelling such a standard way of presenting
-
University spin-out fund makes half a million pound first investments
They will use the cash boost to enable a market launch in the UK and prepare for international expansion with the commercialisation of their new melanoma test AMBLor in the USA
-
Great creative is effective creative. And effective creative is affective creative
One shining example of this can be found in the Melanoma Likes Me campaign from WPP in Australia:. ... Then, the creepy online persona ‘Melanoma’ – would ‘like’, ‘follow’ and comment, in real time.
-
Using Healthtech to Deliver Better Patient Outcomes
Peter Birch, General Manager (Asia Pacific) at MetaOptima Technologies &host of the “ Talking HealthTech Podcast.” joins us to discuss a whole range of topics, including Peter’s professional journey and the work he is doing with the
-
If our patients are diverse, why are clinical trials so white?
According to the largest study (to date) in different racial and ethnic populations across the US, there was no evidence to support the association of UV exposure and melanoma incidence in ... black or Hispanic populations – studies assessing the
More from PMHub
Approximately 3 fully matching, plus 14 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Understanding the ‘real world’ starts and ends with the patient
- Straight outta lockdown – what’s next for flexible working?
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Onyx Health Launch Creative Studio After Record Year
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
